Viking Therapeutics stock jumps 16% after drugmaker moves weight loss injection to late-stage trial

Shares of a biotech company rose after announcing plans to accelerate its weight loss injection into a late-stage trial. The move could bring the drugmaker closer to entering the lucrative market for GLP-1s, projected to reach $150 billion by the end of the decade. The company had previously intended to start a mid-stage trial after positive results from another phase two study in February.